Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study
Treatment with dupilumab compared to systemic agents resulted in reductions in AD-related comorbidities in pediatric patients.
Authors
- Elena B. Hawryluk (ORCID: https://orcid.org/0000-0002-0862-3339)
- Lisa M. Bartnikas (ORCID: https://orcid.org/0000-0002-5148-3271)
- Michiko K. Oyoshi (ORCID: https://orcid.org/0000-0002-0931-3949)
- Serena Yun‐Chen Tsai (ORCID: https://orcid.org/0000-0002-5778-645X)
- Jonathan M. Gaffin (ORCID: https://orcid.org/0000-0003-2213-4504)
- Hana B. Ruran (ORCID: https://orcid.org/0009-0007-3964-4961)
- Lynda C. Schneider (ORCID: https://orcid.org/0000-0002-5633-0178)
- Kevin Sheng‐Kai (ORCID: https://orcid.org/0000-0002-9394-4144)
- Wanda Phipatanakul
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Center for Global Health (US)
- University School (US)
- Case Western Reserve University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Allergy
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1111/all.16265
- Citations
- 19
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 10.16
Funders
- National Eczema Association
- AstraZeneca
- Sanofi
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases